Catalyst Wire Dossier Catalyst Wire Dossier

ABL001

asciminib · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABL001, covering 2022-02-15 to 2022-02-15. Get the full timeline:

Most recent: Clinical Trial Update: Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs [Phase 3]

See pricing